News for Green Cross Corporation (006280.KS)

YONGIN, South Korea , Feb. 11, 2025 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its LSD (lysosomal storage disorder) pipelines at the WORLD Symposium 2025, held from Feb. 3rd to 7th, 2025, in San Diego, USA.

YONGIN, South Korea, Nov. 26, 2024 /PRNewswire/ -- GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with 'GC1130A', an innovative new drug for Sanfillippo syndrome type A (MPS IIIA).

GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies

Owing to the presence of an advanced healthcare system, extensive research and development activities, and high expenditure on biopharmaceuticals, North...

GC Cell and Lukas Announce Strategic Cooperation Agreement to Jointly Tap into the Innovative Cell Therapy including and beyond Korean and Taiwanese Market

FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A

GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance

GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval

Increased participation in clinical trials drives demand for plasma-derived therapies, fostering growth in the plasma fractionation market....

The cytomegalovirus infections market size is expected to grow during the forecast period owing to the expected launch of novel emerging therapies for...

The global plasma fractionation market size is projected to reach USD 49.51 billion by 2030 from its value USD 28.66 billion in 2022, at CAGR of 7.07%...

Read Head-To-Head Analysis: Brickell Biotech (NASDAQ:BBI) vs. BioCryst Pharmaceuticals (NASDAQ:BCRX) at ETF Daily News